Article
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2008
Brandes Alba A, Franceschi Enrico, Tosoni Alicia, Blatt Valeria, Pession Annalisa, Tallini Giovanni, Bertorelle Roberta, Bartolini Stefania, Calbucci Fabio, Andreoli Alvaro, Frezza Giampiero, Leonardi Marco, Spagnolli Federica, Ermani Mario
Abstract excerpt
PURPOSE: Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy. The radiologic images obtained in this setting can be difficult to interpret since they may show radiation-induced pseudopro...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.